Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05905315

Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC (VULCANIZE-II)

Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For Locally Advanced Vulvar Carcinoma

Sponsor: The Netherlands Cancer Institute

Conditions Locally Advanced Vulvar Carcinoma Squamous Cell Carcinoma of the Vulva

Interventions Chemoradiation Paclitaxel and Carboplatin

Updated 5 times since 2023 Last updated: Apr 12, 2024 Started: Jan 1, 2024 Primary completion: Sep 1, 2029 Completion: Sep 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Locally Advanced Vulvar Carcinoma and Squamous Cell Carcinoma of the Vulva, this trial is actively recruiting participants. The trial is conducted by The Netherlands Cancer Institute and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2023 — May 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Netherlands Cancer Institute

Data source: The Netherlands Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands
• Leiden, Netherlands